The Europe Tuberculosis Diagnostics Market would witness market growth of 4.4% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Tuberculosis Diagnostics Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $181.1 million by 2031. The UK market is exhibiting a CAGR of 3.4% during (2024 - 2031). Additionally, The France market would experience a CAGR of 5.3% during (2024 - 2031).
The rise of multidrug-resistant tuberculosis (MDR-TB) represents a significant and growing challenge in the fight against TB. MDR-TB is a form of tuberculosis that is caused by bacteria that are resistant to at least two of the most potent first-line anti-TB drugs, which are rifampicin and isoniazid. This resistance makes MDR-TB much more difficult and costly to treat than drug-susceptible TB, and it has serious implications for public health, as the disease can spread to others, compounding the challenge of TB control. The emergence and spread of MDR-TB have highlighted the critical need for advanced diagnostic tools that can quickly and accurately identify resistant strains, enabling appropriate treatment to be initiated promptly.
The market is not without its challenges. Despite the progress made in developing advanced diagnostic tools, significant barriers remain in terms of accessibility and affordability, particularly in low-income countries where the burden of TB is greatest. Many advanced diagnostic tools are expensive and require infrastructure and expertise, which are often lacking in these settings. This has led to a persistent reliance on older, less effective diagnostic methods, such as smear microscopy, which, while affordable and easy to use, have significant limitations regarding sensitivity and specificity.
TB prevention and awareness programs in France are primarily managed by Santé publique France, the national public health agency. The agency runs national campaigns to raise awareness about TB, particularly in high-incidence areas like Île-de-France. These campaigns often include informational materials distributed in multiple languages to reach immigrant communities and other at-risk groups. The Ministry of Health (Ministero della Salute) coordinates Italy's TB prevention and awareness efforts, focusing on migrant and refugee populations. The country has mandated TB screening for newly arrived asylum seekers as part of a more comprehensive strategy to prevent the transmission of TB within migrant communities. Public health campaigns in Italy are designed to raise awareness about TB symptoms and encourage individuals to seek medical care early. Therefore, as countries across the region continue to implement and refine their TB control strategies, the demand for innovative diagnostics is expected to rise.
Based on End Use, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics, and Others. Based on Type, the market is segmented into Detection of Latent Infection (Skin Test & IGRA), Phage Assay, Detection of Drug Resistance (DST), Nucleic Acid Testing, Radiographic Method, Cytokine Detection Assay, Diagnostic Laboratory Methods, and Other Methods. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany market dominated the Europe Tuberculosis Diagnostics Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $181.1 million by 2031. The UK market is exhibiting a CAGR of 3.4% during (2024 - 2031). Additionally, The France market would experience a CAGR of 5.3% during (2024 - 2031).
The rise of multidrug-resistant tuberculosis (MDR-TB) represents a significant and growing challenge in the fight against TB. MDR-TB is a form of tuberculosis that is caused by bacteria that are resistant to at least two of the most potent first-line anti-TB drugs, which are rifampicin and isoniazid. This resistance makes MDR-TB much more difficult and costly to treat than drug-susceptible TB, and it has serious implications for public health, as the disease can spread to others, compounding the challenge of TB control. The emergence and spread of MDR-TB have highlighted the critical need for advanced diagnostic tools that can quickly and accurately identify resistant strains, enabling appropriate treatment to be initiated promptly.
The market is not without its challenges. Despite the progress made in developing advanced diagnostic tools, significant barriers remain in terms of accessibility and affordability, particularly in low-income countries where the burden of TB is greatest. Many advanced diagnostic tools are expensive and require infrastructure and expertise, which are often lacking in these settings. This has led to a persistent reliance on older, less effective diagnostic methods, such as smear microscopy, which, while affordable and easy to use, have significant limitations regarding sensitivity and specificity.
TB prevention and awareness programs in France are primarily managed by Santé publique France, the national public health agency. The agency runs national campaigns to raise awareness about TB, particularly in high-incidence areas like Île-de-France. These campaigns often include informational materials distributed in multiple languages to reach immigrant communities and other at-risk groups. The Ministry of Health (Ministero della Salute) coordinates Italy's TB prevention and awareness efforts, focusing on migrant and refugee populations. The country has mandated TB screening for newly arrived asylum seekers as part of a more comprehensive strategy to prevent the transmission of TB within migrant communities. Public health campaigns in Italy are designed to raise awareness about TB symptoms and encourage individuals to seek medical care early. Therefore, as countries across the region continue to implement and refine their TB control strategies, the demand for innovative diagnostics is expected to rise.
Based on End Use, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics, and Others. Based on Type, the market is segmented into Detection of Latent Infection (Skin Test & IGRA), Phage Assay, Detection of Drug Resistance (DST), Nucleic Acid Testing, Radiographic Method, Cytokine Detection Assay, Diagnostic Laboratory Methods, and Other Methods. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Abbott Laboratories
- Qiagen N.V
- Thermo Fisher Scientific Inc.
- Becton, Dickinson and Company
- F.Hoffmann-La Roche Ltd.
- Hologic, Inc.
- Danaher Corporation
- DiaSorin S.p.A.
- Bruker Corporation
Market Report Segmentation
By End Use- Diagnostic Laboratories
- Hospitals & Clinics
- Others
- Detection of Latent Infection (Skin Test & IGRA)
- Phage Assay
- Detection of Drug Resistance (DST)
- Nucleic Acid Testing
- Radiographic Method
- Cytokine Detection Assay
- Diagnostic Laboratory Methods
- Other Methods
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe Tuberculosis Diagnostics Market by End Use
Chapter 5. Europe Tuberculosis Diagnostics Market by Type
Chapter 6. Europe Tuberculosis Diagnostics Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Qiagen N.V
- Thermo Fisher Scientific Inc.
- Becton, Dickinson and Company
- F. Hoffmann-La Roche Ltd.
- Hologic, Inc.
- Danaher Corporation
- DiaSorin S.p.A.
- Bruker Corporation
- Revvity, Inc.
Methodology
LOADING...
